BRTI Life Sciences

BRTI Life Sciences was a biotechnology company focused on developing advanced 3D cell culture environments to improve the physiological relevance of life science research. The company's flagship technology, Cell-Mate3D, was a chemically defined, animal-free matrix composed of hyaluronan and chitosan, designed to mimic the natural extracellular matrix without the need for chemical or UV cross-linking. This injectable and biocompatible platform supported a wide range of applications, including cancer research, stem cell differentiation, and regenerative medicine. By providing a more accurate microenvironment, BRTI Life Sciences aimed to bridge the gap between traditional 2D cell culture and in vivo models, enhancing the predictability of drug discovery and disease modeling. Although the company operated for nearly two decades and successfully commercialized its tools, it reportedly ceased operations around late 2022.